The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.
The Cambridge, Massachusetts-based biotech's personalized cancer vaccine mRNA-4157, developed with Merck (MRK), is currently in late-stage development targeting patients with skin cancer melanoma.
Moderna has been utilizing its messenger-RNA technology on personalized cancer vaccines. Its mRNA-4157, in collaboration with Merck & Co. MRK and its blockbuster Keytruda, has proven to cut ...
Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...
It is evaluating multiple candidates in late-stage studies, including mRNA-1647 (cytomegalovirus [CMV] vaccine), mRNA-1010 (influenza vaccine) and mRNA-4157/V940 (individualized neoantigen therapy).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback